

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

NCT06810505

| | |
|-------------------|------------------|
| Status | RECRUITING |
| Phase | Phase 3 |
| Sponsor | AbbVie |
| Enrollment | 420 participants |

Key Eligibility Criteria

Inclusion (5)

- History of chronic migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3) (2018) for at least 6 months as of Visit 1.
- During the last 28 days of the screening/baseline period, and as per eDiary:
- Participant must have completed the eDiary for a minimum of 20 out of 28 days.
- Participant has \geq 15 headache days.
- Participant has \geq 8 migraine days.

Exclusion (2)

- Clinically significant hypertension per investigator's judgment.
- History of any clinically significant hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, cardiovascular or neurologic disease.

Locations (58 total)

Rehabilitation & Neurological Services /ID# 270782, Huntsville, Alabama, United States
Preferred Research Partner, Inc /ID# 270389, Little Rock, Arkansas, United States
Preferred Research Partners /ID# 270419, Little Rock, Arkansas, United States
... and 55 more locations